Which companies are Hangzhou Biotest Biotech's closest peers?

The cockpit's peer set: Advanced Medical Solutions (AMS.L), OrthoPediatrics (KIDS), Beijing Aerospace Changfeng (600855.SS), Maccura Biotechnology (300463.SZ), Shanghai Aladdin Biochemical Technology (688179.SS), Zylox-Tonbridge Medical Technology (2190.HK), Allmed Medical Products (002950.SZ), Cofoe Medical Technology (1187.HK).

Is Hangzhou Biotest Biotech expensive compared with its peers?

On forward p/e it trades at 34.7× against a peer median of 19.3×, 3rd most expensive of 16 in its peer set.

How has Hangzhou Biotest Biotech stock performed?

Over six months to 6 Nov 2026 the shares returned +5.5% against -12.4% for the median peer; over one year -15.9%.

← CockpitCompetitor Analysis › 688767.SS Hangzhou Biotest Biotech Co., Ltd. Class AOpen in the cockpit ↗

Hangzhou Biotest Biotech Co., Ltd. Class A688767.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties

Momentum leader 82

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$824M

US dollars, full cap

Free float

100%

of shares outstanding

$/day

$12.0M

20-day average traded

Fwd P/E

34.7×

forward earnings

ROIC−WACC

-4.5 pp

WACC 7.0%

Hurdle

n/a

no reverse DCF

Next earnings

171 days

26 Apr 2027

Close · CNYCN¥36.80

1D-4.8%

1W-2.8%

1M-8.9%

3M+1.2%

6M+5.5%

YTD-2.6%

1Y-15.9%

ATR %6.0%

52w lowhigh27.8% off high

What Hangzhou Biotest Biotech does

Employees: 613

Hangzhou Biotest Biotech at a glance

Size Hangzhou Biotest Biotech (688767.SS) is a China Health Care company (Medical Specialties) with a market value of $824M, the 2683rd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥36.80 on 6 Nov 2026.

Performance Over six months the shares gained 5.5%, against -12.4% for the median peer and -16.4% for the China market (cap-weighted) — 8th highest of 21 in its peer set.

Growth Revenue fell 4.5% over the last twelve months (peer median +15.3%); the operating margin is 3.2% (peer median 11.4%).

Valuation It trades at 34.7× forward earnings against a peer median of 19.3× (3rd most expensive of 16).

Capital Return on invested capital runs 4.5 points below its cost of capital (7.0% WACC).

Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).

Relative performance

Six months, rebased to 100: Hangzhou Biotest Biotech against the median of its 20 peers (local-currency closes).

Hangzhou Biotest Biotech financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	CN¥452M	CN¥445M	CN¥555M	CN¥439M	CN¥1.88B
Revenue growth	—	-20%	+27%	-77%	—
Gross profit	CN¥221M	CN¥192M	CN¥283M	CN¥208M	CN¥993M
EBITDA	n/a	CN¥35.5M	CN¥135M	CN¥33.1M	CN¥776M
Net income	CN¥10.3M	CN¥49.3M	CN¥170M	CN¥107M	CN¥774M
Free cash flow	-CN¥43.3M	-CN¥16.4M	-CN¥108M	CN¥78.8M	CN¥539M
Capital expenditure	CN¥139M	CN¥130M	CN¥245M	CN¥56.4M	CN¥179M
Total debt	CN¥100M	CN¥18.6M	CN¥440,516	CN¥3.04M	CN¥7.64M

Quarterly statements and history in the cockpit →

Hangzhou Biotest Biotech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Hangzhou Biotest Biotech is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Hangzhou Biotest Biotech is the large dot.

Hangzhou Biotest Biotech competitors and peer comparison

How Hangzhou Biotest Biotech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Hangzhou Biotest Biotech against its 20 peers (data as of 6 Nov 2026)
Measure	688767.SS	Peer median	Rank in peer set
1-month return	-8.9%	-4.6%	8th lowest of 21
6-month return	+5.5%	-12.4%	8th highest of 21
Distance from 52-week high	-27.8%	-31.6%	9th highest of 21
Revenue growth (TTM)	-4.5%	+15.3%	4th lowest of 21
Operating margin	3.2%	11.4%	5th lowest of 21
Forward P/E	34.7×	19.3×	3rd most expensive of 16
ROIC minus cost of capital	-4.5 pp	+1.3 pp	5th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	Forward P/E	Req g	Delivered g
Hangzhou Biotest Biotech 688767.SS	China	$824M	+5%	-4%	3%	34.7×	n/a	n/a
Advanced Medical Solutions AMS.L	United Kingdom	$824M	+14%	+6%	12%	20.7×	19.6%	+21.4%
OrthoPediatrics KIDS	United States	$829M	+78%	+16%	-8%	n/a	n/a	n/a
Beijing Aerospace Changfeng 600855.SS	China	$832M	-35%	-10%	-19%	n/a	n/a	n/a
Maccura Biotechnology 300463.SZ	China	$814M	-14%	-1%	-4%	164.7×	9.2%	-10.2%
Shanghai Aladdin Biochemical Technology 688179.SS	China	$806M	-25%	+39%	26%	30.0×	21.1%	+24.2%
Zylox-Tonbridge Medical Technology 2190.HK	Hong Kong	$851M	-13%	+39%	25%	15.9×	5.5%	+105.8%
Allmed Medical Products 002950.SZ	China	$798M	-39%	+14%	8%	n/a	n/a	n/a
Cofoe Medical Technology 1187.HK	Hong Kong	$798M	-27%	+40%	10%	12.5×	-8.0%	+6.6%
Standard Engineering Technology SETL.NS	India	$796M	+164%	+26%	13%	n/a	n/a	n/a
Beta Bionics BBNX	United States	$854M	+63%	+44%	-73%	n/a	n/a	n/a
Menicon 7780.T	Japan	$854M	+12%	+5%	9%	19.3×	n/a	n/a
MedCap MCAP.ST	Sweden	$864M	+6%	+17%	15%	26.4×	2.9%	+20.9%
JINS 3046.T	Japan	$865M	-12%	+14%	10%	16.6×	-7.2%	+11.7%
Shanghai INT Medical Instruments 1501.HK	Hong Kong	$784M	-25%	+35%	21%	17.8×	-2.1%	+23.5%
Sino Medical Sciences Technology 688108.SS	China	$868M	-35%	+22%	19%	69.2×	31.0%	+9.9%
Varex Imaging VREX	United States	$783M	-10%	+5%	8%	20.3×	n/a	n/a
BMC Medical 301367.SZ	China	$780M	-13%	+37%	17%	19.8×	0.1%	+15.6%
Modern Dental 3600.HK	Hong Kong	$871M	+19%	+12%	22%	8.8×	-7.0%	+11.3%
InMode INMD	United States	$767M	-5%	-7%	18%	10.1×	-10.5%	+12.4%
Cisen Pharmaceutical 603367.SS	China	$890M	-15%	-6%	8%	8.3×	-12.9%	-1.3%

Questions

Which companies are Hangzhou Biotest Biotech's closest peers?: The cockpit's peer set: Advanced Medical Solutions (AMS.L), OrthoPediatrics (KIDS), Beijing Aerospace Changfeng (600855.SS), Maccura Biotechnology (300463.SZ), Shanghai Aladdin Biochemical Technology (688179.SS), Zylox-Tonbridge Medical Technology (2190.HK), Allmed Medical Products (002950.SZ), Cofoe Medical Technology (1187.HK).
Is Hangzhou Biotest Biotech expensive compared with its peers?: On forward p/e it trades at 34.7× against a peer median of 19.3×, 3rd most expensive of 16 in its peer set.
How has Hangzhou Biotest Biotech stock performed?: Over six months to 6 Nov 2026 the shares returned +5.5% against -12.4% for the median peer; over one year -15.9%.